Sector News

AstraZeneca R&D boss Morrison leaves to head private drugmaker

June 10, 2015
Life sciences
(Reuters) – AstraZeneca’s chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group’s research operations.
 
A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States, adding there had been no disagreement with other top managers at AstraZeneca.
 
“It is not appropriate for us to confirm the name of the company but it is an exciting new opportunity for him,” she said.
 
Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker’s bid to turn around its portfolio. He also helped defend the firm’s independence in the face of a $118 billion takeover attempt by Pfizer last year.
 
Morrison will cease his current roles at the end of the week and leave AstraZeneca shortly after.
 
While the drugmaker seeks a successor, Chief Executive Pascal Soriot will take over responsibility for medicines development and Elisabeth Bjork will act as chief medical officer.
 
Soriot, who took over as CEO in October 2012, chose Morrison as one of his key drug research lieutenants, alongside Mene Pangalos, who heads early development work, and Bahija Jallal, leader of the group’s MedImmune biotech unit.
 
AstraZeneca has won plaudits for recent progress with its pipeline of experimental drugs, especially in cancer, where it is investing heavily in the hot new field of immunotherapy.
 
Still, many industry analysts remain sceptical about its ability to lift sales to $45 billion by 2023 from $26 billion last year, a target set by Soriot when the company was fighting off Pfizer’s attempted takeover last year.
 
It has suffered some setbacks, too, most recently when its partner Amgen pulled out of a psoriasis drug collaboration last month after suicidal thoughts were observed in patients taking the medicine.
 
AstraZeneca said it had not issued a formal statement about Morrison’s exit because he was not a board member. 
 
By Ben Hirschler (Editing by David Holmes)

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach